Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 13/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 4/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26414965 | 0.89 | THRB (0.46) | THRBBRD4BRD2BRD3THRA | |
| SCHEMBL30611102 | 0.89 | THRB (0.46) | THRBBRD4BRD2BRD3THRA | |
| SCHEMBL23663157 | 0.81 | THRB (0.45) | THRBTHRA | |
| SCHEMBL30014130 | 0.80 | CTSL (0.40) | BRD4BRD2BRD3 | |
| SCHEMBL23663295 | 0.80 | CTSL (0.40) | BRD4BRD2BRD3 | |
| SCHEMBL23663207 | 0.80 | CTSL (0.40) | BRD4BRD2BRD3 | |
| SCHEMBL26410468 | 0.80 | THRB (0.50) | THRBBRD4BRD2BRD3THRA | |
| SCHEMBL30013840 | 0.79 | THRB (0.45) | THRBBRD4BRD2BRD3THRA | |
| SCHEMBL4964380 | 0.78 | THRB (0.57) | THRBBRD4BRD2BRD3THRA | |
| SCHEMBL7208159 | 0.78 | THRB (0.57) | THRBBRD4BRD2BRD3THRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| WO-2021143706-A1 | SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2021-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | THRB 3/4885BRD4 4160/4885BRD2 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.